Of note, the shorter median time from onset of attack to first icatibant administration for patients with HAE nC1-INH may have contributed to the improved time-to-event outcomes compared with patients with HAE-1/2, in line with previously published IOS data showing that earlier administration of icatibant results in more rapid resolution of HAE attacks.28 This evidence concerns the gene COL18A1 and hereditary angioedema.